SBRT for recurrent head and neck cancer

Research output: Contribution to journalArticle

Abstract

The management of patients with recurrent head and neck cancers is complex. Concerns over toxicity with re-irradiation have limited its use in the clinical setting. Stereotactic Body Radiation Therapy (SBRT) has emerged as a highly conformal and precise type of radiotherapy and has the advantage of sparing normal tissue. Although SBRT is an attractive treatment modality, its use in the clinic is limited, given the technically challenging nature of the procedure. In this review, we attempt to provide a comprehensive overview of the role of re-irradiation in patients with recurrent head and neck cancers, with particular attention to the advent of SBRT and its use with systemic therapies such as cetuximab.

Original languageEnglish (US)
Article number012025
JournalJournal of Physics: Conference Series
Volume777
Issue number1
DOIs
StatePublished - Feb 3 2017

Fingerprint

radiation therapy
cancer
irradiation
toxicity
therapy

ASJC Scopus subject areas

  • Physics and Astronomy(all)

Cite this

SBRT for recurrent head and neck cancer. / Garg, Madhur K.; Kabarriti, Rafi; Baliga, S.; Guha, Chandan; Tome, Wolfgang A.; Kalnicki, Shalom.

In: Journal of Physics: Conference Series, Vol. 777, No. 1, 012025, 03.02.2017.

Research output: Contribution to journalArticle

@article{601a7c872eb849afbd280dc3c27830ca,
title = "SBRT for recurrent head and neck cancer",
abstract = "The management of patients with recurrent head and neck cancers is complex. Concerns over toxicity with re-irradiation have limited its use in the clinical setting. Stereotactic Body Radiation Therapy (SBRT) has emerged as a highly conformal and precise type of radiotherapy and has the advantage of sparing normal tissue. Although SBRT is an attractive treatment modality, its use in the clinic is limited, given the technically challenging nature of the procedure. In this review, we attempt to provide a comprehensive overview of the role of re-irradiation in patients with recurrent head and neck cancers, with particular attention to the advent of SBRT and its use with systemic therapies such as cetuximab.",
author = "Garg, {Madhur K.} and Rafi Kabarriti and S. Baliga and Chandan Guha and Tome, {Wolfgang A.} and Shalom Kalnicki",
year = "2017",
month = "2",
day = "3",
doi = "10.1088/1742-6596/777/1/012025",
language = "English (US)",
volume = "777",
journal = "Journal of Physics: Conference Series",
issn = "1742-6588",
publisher = "IOP Publishing Ltd.",
number = "1",

}

TY - JOUR

T1 - SBRT for recurrent head and neck cancer

AU - Garg, Madhur K.

AU - Kabarriti, Rafi

AU - Baliga, S.

AU - Guha, Chandan

AU - Tome, Wolfgang A.

AU - Kalnicki, Shalom

PY - 2017/2/3

Y1 - 2017/2/3

N2 - The management of patients with recurrent head and neck cancers is complex. Concerns over toxicity with re-irradiation have limited its use in the clinical setting. Stereotactic Body Radiation Therapy (SBRT) has emerged as a highly conformal and precise type of radiotherapy and has the advantage of sparing normal tissue. Although SBRT is an attractive treatment modality, its use in the clinic is limited, given the technically challenging nature of the procedure. In this review, we attempt to provide a comprehensive overview of the role of re-irradiation in patients with recurrent head and neck cancers, with particular attention to the advent of SBRT and its use with systemic therapies such as cetuximab.

AB - The management of patients with recurrent head and neck cancers is complex. Concerns over toxicity with re-irradiation have limited its use in the clinical setting. Stereotactic Body Radiation Therapy (SBRT) has emerged as a highly conformal and precise type of radiotherapy and has the advantage of sparing normal tissue. Although SBRT is an attractive treatment modality, its use in the clinic is limited, given the technically challenging nature of the procedure. In this review, we attempt to provide a comprehensive overview of the role of re-irradiation in patients with recurrent head and neck cancers, with particular attention to the advent of SBRT and its use with systemic therapies such as cetuximab.

UR - http://www.scopus.com/inward/record.url?scp=85014081418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014081418&partnerID=8YFLogxK

U2 - 10.1088/1742-6596/777/1/012025

DO - 10.1088/1742-6596/777/1/012025

M3 - Article

AN - SCOPUS:85014081418

VL - 777

JO - Journal of Physics: Conference Series

JF - Journal of Physics: Conference Series

SN - 1742-6588

IS - 1

M1 - 012025

ER -